FDA Expands Dupilumab for EoE to Younger Children

Dupilumab is now indicated for the treatment of eosinophilic esophagitis in children as young as 1 year and weighing at least 15 kg.

Related Keywords

Regeneron Sanofi ,Drug Administration ,Medscape Medical ,Pediatric Eoe ,Symptom Questionnaire ,Biologic Therapy ,Iologics ,Otolaryngology ,Nt Specialty ,Ead And Neck Surgery Ent Speciality ,Children ,Child ,Childhood ,Ediatrics ,Kids ,Eosinophilic Esophagitis Oesophagitis ,Esophagitis ,Remission ,Upper Respiratory Infection ,Upper Respiratory Tract Infection ,Arthralgia ,Ainful Joint ,Joint Pain ,Caregiver ,Esophagus ,Oesophageal ,Us Food And Drug Administration ,